Comparison of Efficacy Between Nighttime and Daytime Peritoneal Dialysis

Not Applicable

Recruiting

• Conditions: End-Stage Kidney Disease; Peritoneal Dialysis

• Registration Number: NCT05449067
• Lead Sponsor: Nanfang Hospital, Southern Medical University

Brief Summary

Background: Compared with continuous ambulatory peritoneal dialysis (CAPD), nocturnal continuous cyclic peritoneal dialysis (NCPD) uses a machine to exchange fluid to perform dialysis at night, allowing patients to work or study normally during daytime. Since the dialysis fluid retention time of NCPD patients is shorter than that of CAPD, this RCT was designed to investigate whether there is a difference in the efficacy between the two modalities on peritoneal dialysis.

Design: Randomized, open-label, cross-over, multi-center clinical trial.

Objective:

Primary Objective: To compare the adequacy of peritoneal dialysis between NCPD and CAPD in non-diabetic patients.

Secondary Objective: To compare the effects of NCPD and CAPD on the quality of life, including sleep quality, nocturnal blood pressure, and ultra-filtration volume in non-diabetic patients.

Hypothesis: In non-diabetic patients, NCDP is non-inferior to CAPD in peritoneal dialysis adequacy.

Methods: A total of 124 non-diabetic peritoneal dialysis patients will be enrolled and randomly assgined into two groups in a 1:1 ratio. Patients in group A will receive NCPD treatment from 1 to 12 weeks and then switch to CAPD treatment from 13 to 24 weeks, while patients in group B will receive CAPD treatment from 1 to 12 weeks and then switch to NCPD treatment from 13 to 24 weeks. All patients are required to sign an informed consent before enrollment. The enrolled patients are planned to be followed every 4 weeks, and unplanned visits will be arranged if necessary. The peritoneal dialysis adequacy (weekly total Kt/V) of the patients will be assessed at baseline and at the corresponding visit points. The average daily ultra-filtration volume during the two modalities of treatment will be compared. Sleep quality parameters will be collected using a contact-free continuous vital signs monitoring equipment at baseline, Week 12 and Week 24. The health-related quality of life and social function will be analyzed using the Kidney Disease Quality of Life 36-item short form survey (KDQOL-36) and Social Disability Screening Schedule (SDSS) questionnaire. Twenty-four-hour Ambulatory Blood Pressure (ABP) will be monitored at baseline, Week 12, and Week 24.

Detailed Description

Sample Size Estimation:

Clinical data from previous studies showed that the total weekly Kt/V of non-diabetic peritoneal dialysis patients was 2.4 (95% CI: 1.46-3.38), the change in Kt/V after 3 months of treatment was -0.02 (95% CI: -0.64-0.59), and the standard deviation of the change was 0.31 (95% CI: 0.26-0.36). Based on the above data, we estimated the sample size.

For the primary efficacy outcome (the difference of Kt/V score between NCPD and CAPD patients), the non-inferiority test shows that 110 patients could provide 90% power to detect an absolute difference of 0 when the margin of non-inferiority is 0.1 with a common standard deviation of 0.36 at one-sided significance level α=0.025. Considering the 10% rate of loss to follow-up, 124 cases (62 cases in each sequence) will be enrolled.

Study Timeline

• Study Start: 2022-05-26
• Study First Submitted: 2022-06-22
• Study First Submitted QC: 2022-07-03
• Study First Posted: 2022-07-08
• Status Verified: 2025-07
• Last Update Submitted: 2025-07-14
• Last Update Posted: 2025-07-17
• Primary Completion: 2025-12-30
• Study Completion: 2025-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 124

Inclusion Criteria

1. Age 18 to 75 years;
2. Maintenance peritoneal dialysis for ≥ 1 month;
3. Weekly total CrCL ≥ 45 liters/week/1.73m2 body surface area;
4. Total weekly Kt/V ≥ 1.7.

Exclusion Criteria

1. Patients with diabetes mellitus;
2. Maintained peritoneal dialysis solution with a glucose concentration >2.5%;
3. Combined with acute events of cardiovascular disease(CVD), cardiac function ≥ New York Heart Association (NYHA) class III;
4. Episodes of peritonitis in the past 1 month;
5. Abdominal surgery other than PD catheter insertion in the past 3 months;
6. Planned kidney transplant in the last 6 months;
7. Active hepatitis, cirrhosis, psychiatric disease, malignancy, pregnancy.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
Total Weekly Kt/V	Week 0, 4, 8, 12, 16, 20, and 24	Total weekly Kt/V will be detected at baseline and every visit point (Week 0, 4, 8, 12, 16, 20, and 24). The mean total weekly Kt/V score during NCPD treatment will be compared with that of CAPD.; Standardized formula will be used to calculate total weekly Kt/V score: Kt/V = Kd×T/V. Kd is peritoneal urea nitrogen removal rate. T is the time (unit: min). V represents the urea distribution volume (weight×0.58).

Secondary Outcome Measures

Name	Time	Method
Sleep Quality	Week 12, and 24	Sleep quality will be monitored by a contact-free continuous vital signs monitoring equipment at Week 12 and Week 24. Total sleep duration, time required to fall asleep, duration and proportion of deep/light sleep/REM phases, awake duration, and number of body movements will be reported after sleep monitoring.
Health-related Quality of Life and Social Function	Week 0, 12, and 24	Kidney Disease Quality of Life Short Form 36 (KDQOL-36), a self-reported questionnaire, will be assessed at baseline, Week 12, and Week 24. The total scores will be calculated to evaluate the health-related quality of life at every module after transformed raw scores linearly to a range of 0 (minimum value) to 100 (maximum value) .; Social Disability Screening Schedule (SDSS) questionnaire will be assessed at baseline, Week 12, and Week 24. The total score will be calculated to evaluate the social function.
Ambulatory Blood Pressure (ABP)	Week 0, 12, and 24	Twenty-four-hour ABP will be monitored at baseline, Week 12, and Week 24, including daytime average blood pressure, nocturnal average blood pressure, and blood pressure variability.
Peritoneal Ultrafiltration Volume (UV)	Everyday during treatment	Peritoneal UV will be recorded daily during treatment. The average peritoneal UV will be compared between the two modalities.; Net ultrafiltration volume will be calculated as the volume of the drained dialysate (L) minus the volume of infused dialysis fluid (L).

Trial Locations

Locations (1)

Nanfang Hospital of Southern Medical University; 🇨🇳 Guangzhou, Guangdong, China